Literature DB >> 8526910

Deletion and transfection analysis of the p15/MTS2 gene in malignant gliomas.

M Tenan1, S Benedetti, G Finocchiaro.   

Abstract

We have investigated the status of the MTS2 gene, encoding the cyclin-dependent kinase (CDK) inhibitor p15, in 32 glioblastomas. Semi-quantitative PCR identified 7 tumors in which the amplified material was 18.6% of controls and 7 in which was 48.0%, suggesting the occurrence of homozygous and hemizygous deletions, respectively. Single strand conformation polymorphism analysis identified one polymorphism but no mutations. We also expressed MTS2 and MTS1, encoding the contiguous and highly homologous CDK inhibitor p16, in U-87 human glioblastoma cells. Both genes, either separately or in combination, inhibit significantly the proliferation rate of U-87 cells but such inhibition is progressively lost. As a whole, the data assign a tumor suppressor role to p15 and confirm homozygous deletions as the favorite mechanism for the inactivation of MTS1 and MTS2 in glioblastomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8526910     DOI: 10.1006/bbrc.1995.2763

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Conditional expression of the tumor suppressor p16 in a heterotopic glioblastoma model results in loss of pRB expression.

Authors:  Matthias Simon; Christian Simon; Gertraud Köster; Volkmar H J Hans; Johannes Schramm
Journal:  J Neurooncol       Date:  2002-10       Impact factor: 4.130

Review 2.  Delivery of cell cycle genes to block astrocytoma growth.

Authors:  J Fueyo; C Gomez-Manzano; T J Liu; W K Yung
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

3.  Exogenous expression of p16INK4a is associated with decrease in telomerase activity.

Authors:  H Sawa; H Kamada; T A Ohshima; A Noguchi; N Itoh; K Saruta; M Hara; I Saito
Journal:  J Neurooncol       Date:  1999-03       Impact factor: 4.130

4.  Expression studies in gliomas and glial cells do not support a tumor suppressor role for LGI1.

Authors:  Tiziana Piepoli; Cemile Jakupoglu; Wenli Gu; Elena Lualdi; Blanca Suarez-Merino; Pietro L Poliani; Maria Grazia Cattaneo; Barbara Ortino; Dorota Goplen; Jian Wang; Rosa Mola; Francesca Inverardi; Carolina Frassoni; Rolf Bjerkvig; Ortrud Steinlein; Lucia M Vicentini; Oliver Brüstle; Gaetano Finocchiaro
Journal:  Neuro Oncol       Date:  2006-03-02       Impact factor: 12.300

5.  Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours.

Authors:  E E Schmidt; K Ichimura; K R Messerle; H M Goike; V P Collins
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.